To carry out their activities, Research Teams of the Frédéric Joliot Institute for Life Sciences have developed high-profile technological platforms in many areas : biomedical imaging, structural biology, metabolomics, High-Throughput screening, level 3 microbiological safety laboratory...
All the news of the Institute of life sciences Frédéric Joliot
News | Article | Brain | Diseases
Aloïse Mabondzo, research director, head of the Neurovascular Pharmacology Group of the SPI (DMTS), co-founder and scientific director (CSO) of CERES BRAIN THERAPEUTICS, has just obtained funding of nearly one million US dollars from the prestigious National Institute of Health for his project « Neuroprotective Strategy: Novel Purine Derivatives for Neonatal Hypoxia-ischemia ».
Aloïse Mabondzo has been interested for some years in the pharmacological properties of certain purine derivatives, such as the attenuation of mechanisms involved in the pathogenesis of brain lesions observed in neurodegenerative diseases. In 2018, he filed a patent entitled "Purine Derivatives For Use As Medicament And For Use In Treating Neurodegenerative Or Neuro-Inflammatory Disorders" which aims to provide purine derivatives for the prevention and/or treatment of neurodegenerative disorders (Alzheimer's, Parkinson's, Huntington's, Amyotrophic Lateral Sclerosis, Down's Syndrome) and neuro-inflammation associated disorders.That same year, A.Mabondzo began a collaboration with two leading American partners in the fields of brain injury pathogenesis and of the development of innovative strategy to study the passage of therapeutic molecules across the BBB: respectively, Dr. Barbara Stonestreet, professor of pediatrics, neonatologist at Women & Infants Hospital in Providence, Brown University (Rhode Island) and Dr. William A. Banks, professor of medicine at the University of Washington School of Medicine, Seattle. In October 2019, Barbara Stonestreet and Aloise Mabondzo decide to submit a project to the NIH, as PI and Co-PI respectively, and also submit, in April 2020, a joint patent entitled "Purine Derivatives as Drugs for the Treatment of Neonatal Hypoxia-Ischemia Brain Injury and Related Diseases". Finally, in February 2021, Aloïse Mabondzo receives the final acceptance of the NIH funding for his project with Barbara, an amount of $3M over 5 years, including $1M for her laboratory! The project accepted today by the NIH aims to pursue the development of a promising drug candidate (BRT001) against neonatal hypoxic-ischemic encephalopathy (HIE) in newborns at or near term. A Mabondzo brings along two researchers from the Joliot institute, Fawzi Boumezbeur and Sébastien Mériaux (NeuroSpin), who will be involved in the monitoring of long-term changes in brain anatomy, vasculature and microstructure using in vivo MRI at ultra-high magnetic field in animals that recovered from neonatal HIE related brain injury with and without BRT001 treatment. This also demonstrates the capacity of Joliot researchers to develop strong transversal axes, on both major and global medical issues.Contacts : Aloïse Mabondzo ; Isabelle Philippe
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.